<DOC>
	<DOCNO>NCT01268072</DOCNO>
	<brief_summary>The primary objective study identify biomarkers use evaluation efficacy subject present AECOPD</brief_summary>
	<brief_title>A Study Evaluate Biomarkers Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description>Identify biomarkers use evaluation efficacy subject present AECOPD evaluate longitudinal change interrelationship blood sputum biomarkers physiological endpoint symptom measure stable subject COPD likely experience future AECOPD , subject severe AECOPD .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Age ≥ 40 year time screen Written informed consent locally require authorization ( eg , HIPAA USA , EU Data Privacy Directive EU ) obtain subject prior performing protocolrelated procedure , include screen evaluation . Cohort 1 : A primary diagnosis clinically stable physiciandiagnosed COPD upon entry study meet one follow criterion : Subjects experience severe AECOPD require inpatient hospitalization previous 12 month Subject one severe AECOPD require ED visit past 9 month Subjects currently LTOT . Cohort 1 : Stable COPD 4 week prior screen , defined change ICS therapy use oral corticosteroid antibiotic respiratory tract infection . Cohort 1 : Forced expiratory volume one second ( FEV1 ) /forced vital capacity ( FVC ) &lt; 0.70 low limit normal ( LLN ) . Cohort 1 : FEV1 &lt; 60 % predict normal value . Cohort 2 : A primary diagnosis physiciandiagnosed AECOPD require admission hospital . Current smoker exsmoker tobacco history ≥ 10 packyears ( one pack year = 20 cigarette smoke per day 1 year ) . Ability willingness complete appropriate followup period time require protocol . Able read write use electronic device ( English Spanish version ) . Participation ( define administration least one dose investigational product ) another clinical study , last followup visit within 12 week ( small molecule drug ) ( 6 month large molecule drug ) entry study . Any condition , opinion investigator would interfere interpretation subject safety study result . Employees clinical study site individual involve conduct study , immediate family member individual . The presence another chronic pulmonary systemic disease , opinion investigator medical monitor might affect analysis data ( eg , idiopathic pulmonary fibrosis , sarcoidosis , active cancer autoimmune disease ) . History immunodeficiency . Current alcohol drug abuse history unsuccessfully treat alcohol drug abuse within past year . Cohort 2 : Diagnosis acute disease/condition ( eg , congestive heart failure , acute myocardial infarction , pneumonia , pulmonary embolus ) primary reason subject 's hospitalization .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>COPD</keyword>
</DOC>